
Warm nights and ill premature babies?
A study from Hanover investigates the spread of Klebsiella in the neonatal intensive care unit.

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.
This year's TWINCORE Symposium
Pathways to infection resilience
will take place on 3 - 4 September.

A study from Hanover investigates the spread of Klebsiella in the neonatal intensive care unit.

TWINCORE researchers investigate gene activity in host cells

Diverse Origins – One Goal
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Pashai Fakhri M, Börner F, Held J, Sivaraman K, Fuge J, Rupp J, Barten-Neiner G, Pletz M, Witzenrath M, Rohde G, Rademacher J, Hinze C, Janciauskiene S, CAPNETZ Study Group
Ruijten S, Dos Santos J, Rios-Vazquez V, Navas A, Maas H, Groenendijk A, Blaauw M, van Eekeren L, Vos W, Knoll R, Kumar Gupta M, Ter Horst R, Botey-Bataller J, van Unen N, Li Y, Aschenbrenner A, Schultze J, Xu C, Netea M, van der Ven A, Matzaraki V
Lunding H, Wasynczuk A, Bartsch Y, Buhre J, Nouta J, Leliavski A, Lehrian S, Becker A, Manzhula K, Köcher P, Mehlfeld J, Rahmöller J, Wuhrer M, Ehlers M
The project is researching how the effect of monoclonal antibodies can be improved. These antibodies are already being used successfully against viruses. The aim is to optimize the so-called Fc effector functions in order to fight infections even more effectively.
This project focuses on lung infections such as influenza, COVID-19, pneumonia and tuberculosis in order to improve diagnostics, patient stratification and therapy. RNA molecules and metabolites are being investigated as biomarkers and complementary therapies.
Older people are at high risk of a poor immune response to the flu vaccine. Together with partners, we are looking for biomarkers and risk factors for this inadequate response and are investigating ways to improve the vaccination response.
By applying statistical genetics methods to pathogen genome sequences, we aim to identify and validate genetic determinants of phenotypes such as pathogenicity, virulence and antibiotic resistance, e.g. in E. coli and P. aeruginosa.
Ralf Meister, Bishop of the Evangelical-Lutheran Church of Hanover
“Participation and Resilience at the Interface between Science and Society”
Pathways to Infection Resilience
"Why is knowledge in regulatory science important for translational medicine and basic science?"

